Freehand Secures $75 Million in Latest Series B Funding Round

Freehand secured $75 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Freehand Raises $75 million in Funding

Freehand is tracked by Capvizr.

Investors Behind the Funding

The round was backed by Nexus Venture Partners. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Freehand operates in Healthcare & Life Sciences. Freehand's financing adds to recent private-market activity.

Strategic Use of Funds

The company is expected to use the new capital to expand its platform, support customers, and continue scaling.

Looking Ahead

a significant step up

Source reference: original announcement/article.